Real‐world persistence of multiple sclerosis disease‐modifying therapies
European Journal of Neurology2024Vol. 31(7), pp. e16289–e16289
Citations Over TimeTop 10% of 2024 papers
Emma Tallantyre, Ruth Dobson, Joseph L. J. Froud, Frederika A. St John, Valerie Anderson, Tarunya Arun, Lauren Buckley, Nikos Evangelou, Helen Ford, Ian Galea, Sumi George, Orla Gray, Aimee Hibbert, Mo Hu, Stella E. Hughes, Gillian Ingram, Seema Kalra, Chia‐Hui E. Lim, Joela Mathews, Gavin McDonnell, Naomi Mescall, Sam Norris, Stephen Ramsay, Claire M Rice, Melanie Russell, Marianne Shawe‐Taylor, Thomas Williams, Katharine Harding, Neil P. Robertson
Abstract
Immune reconstituting DMTs may have the highest potential to offer a single treatment for relapsing MS. Comparative data on DMT persistence and reasons for discontinuation are valuable to inform treatment decisions and in personalizing treatment in MS.
Related Papers
- → Natalizumab discontinuation in a Dutch real-world cohort(2021)6 cited
- → Alemtuzumab and multiple sclerosis(2014)3 cited
- → PND12 - NATALIZUMAB VERSUS GLATIRAMER ACETATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS(2018)1 cited
- → PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY(2008)2 cited
- → PND22 Pharmacoeconomic Assessment of Natalizumab in the Treatment of Multiple Sclerosis(2012)